There are no presymptomatic diagnostic tests for Alzheimer's disease (AD) thus limiting experimentation with any potential disease prevention strategy. The goal of this 5-year longitudinal project is to evaluate whether brain amyloid imaging using positron emission tomography (PIB-PET) and CSF tau biomarkers that are biologically valid for the brain changes of AD: a) predict cognitive decline in cognitively normal (NL) subjects;and b) confirm and improve predictions of cognitive decline over hippocampus (HIP) glucose metabolism (MRglc) scanning with FDG-PET. In the current cycle we created and validated the automated HipMask image analysis procedure to sample HIP and other regional MRglc on FDG-PET. HIP MRglc sampling accurately predicted the conversion of NL to MCI and to autopsy confirmed AD. However, MRglc measures lack pathological specificity for AD. The definite diagnosis of """"""""brain AD"""""""" requires detection of neurofibrillary tangles (tauopathy) and amyloid beta (A2) plaques. At post mortem, AD lesions in NL subjects are associated with mild memory impairments, but the risk for the future cognitive symptoms cannot be known. We also initiated longitudinal CSF AD-biomarker studies and extended HipMask to sampling the PET PIB scan used for imaging amyloid beta (A2). Our preliminary studies suggest that CSF biomarkers and PIB-PET imaging can bridge the gap between preclinical data and pathological confirmation. Our data show that elevated levels of CSF P-tau231 (reflecting tauopathy) are: 1) associated with reduced entorhinal cortex MRglc in NL ApoE 54 carriers with subjective memory complaints;2) predict decline from MCI to AD;3) are exclusively brain derived;and 4) are diagnostically specific for AD. Our pilot PIB-PET studies show accentuated prefrontal cortex A2 pathology in both MCI and AD relative to control. Our plan is to test whether the biologically specific CSF P-tau231 and PIB-PET biomarkers contribute to the non-specific HIP MRglc in the prediction of cognitive decline in NL. We will study 110 NL subjects (65-80 yrs). To observe adequate numbers showing declining memory and MCI, 80 individuals with subjective memory complaints will also have a history of a first-degree relative with AD after age 65. This confers a 30% aggregate risk of decline over 3-years. We will conduct three clinical exams at 18-month intervals. FDG and PIB-PET scans and CSF will be obtained twice, at baseline and after 3-years. We will test three major hypotheses: 1) among the imaging and CSF measures, the superior predictors are: HIP MRglc (FDG-PET), P-tau231 (CSF), and prefrontal PIB uptake (PIB-PET);2) P-tau231 (tauopathy) and prefrontal PIB (A2) measures both contribute to the HIP MRglc prediction of outcome;3) CSF and imaging biomarkers can be staged as having diagnostic value in early (presymptomatic) or in later (symptomatic) clinical stages. We will use standardized and quality controlled protocols and there is adequate power for hypothesis testing.

Public Health Relevance

Future prevention trials for Alzheimer's disease will require accurate identification of normal individuals at increased risk for cognitive decline. Currently, FDG-PET is the best tool for the prediction of AD in presymptomatic subjects;however, this modality is not specific for """"""""brain AD"""""""". This project will test the hypothesis that validated biological markers for neurofibrillary tangle and amyloid plaque pathology contribute to FDG-PET in predicting future cognitive decline in cognitively normal subjects.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BDCN-N (02))
Program Officer
Hsiao, John
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
Schools of Medicine
New York
United States
Zip Code
Snyder, Heather M; Carare, Roxana O; DeKosky, Steven T et al. (2018) Military-related risk factors for dementia. Alzheimers Dement 14:1651-1662
Mosconi, Lisa; Walters, Michelle; Sterling, Joanna et al. (2018) Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer's disease: a cross-sectional study of middle-aged adults from the broader New York City area. BMJ Open 8:e019362
Ramos-Cejudo, Jaime; Wisniewski, Thomas; Marmar, Charles et al. (2018) Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link. EBioMedicine 28:21-30
Chen, Jingyun; Li, Yi; Pirraglia, Elizabeth et al. (2018) Quantitative evaluation of tau PET tracers 18F-THK5351 and 18F-AV-1451 in Alzheimer's disease with standardized uptake value peak-alignment (SUVP) normalization. Eur J Nucl Med Mol Imaging 45:1596-1604
de Leon, Mony J; Li, Yi; Rusinek, Henry (2018) Reply: Cerebrospinal Fluid, Hyposmia, and Dementia in Alzheimer Disease: Insights from Dynamic PET and a Hypothesis. J Nucl Med 59:718-719
Sharma, Ram A; Varga, Andrew W; Bubu, Omonigho M et al. (2018) Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study. Am J Respir Crit Care Med 197:933-943
Solesio, MarĂ­a E; Peixoto, Pablo M; Debure, Ludovic et al. (2018) Carbonic anhydrase inhibition selectively prevents amyloid ? neurovascular mitochondrial toxicity. Aging Cell :e12787
Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384
de Leon, Mony J; Li, Yi; Okamura, Nobuyuki et al. (2017) Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET. J Nucl Med 58:1471-1476
Kim, H-J; Oh, S-I; de Leon, M et al. (2017) Structural explanation of poor prognosis of amyotrophic lateral sclerosis in the non-demented state. Eur J Neurol 24:122-129

Showing the most recent 10 out of 109 publications